Adoptive immunotherapy for herpesviruses
- 16 August 2007
- book chapter
- Published by Cambridge University Press (CUP)
- p. 1318-1331
Abstract
Introduction Herpesvirus infections rarely cause significant problems in the immunocompetent human host. However, in the immunosuppressed, for example, recipients of hematopoietic stem cell transplants (HSCT) (Rooney et al., 1998), solid organ transplants (SOT), or human immunodeficiency virus (HIV)-infected individuals, viral infections/reactivations are common and are associated with considerable morbidity and mortality. The resultant uncontrolled infections correlate with a lack of cellular immunity against viral antigens (Weinberg et al., 2001). While effective antiviral drugs are available for the treatment of some herpesvirus infections, adoptive immunotherapy, which is the artificial reconstitution of virus-specific T-cells with in vitro expanded cytotoxic T-lymphocytes (CTLs), for the prophylaxis and/or treatment of herpesviruses is an attractive option. The γ-herpesvirus, Epstein–Barr virus (EBV) is also associated with a heterogeneous range of malignancies and diseases that occur in apparently immunocompetent individuals and since these malignancies also express “foreign” viral antigenic targets they may also be good candidates for immunotherapy (Rickinson and Kieff, 2001). The advances in such adopt ive immunotherapeutic approaches will be discussed in this chapter. Therapy for herpesvirus-related infections and diseases Infectious complications relating to herpes simplex virus (HSV), varicella zoster virus (VZV) (Asanuma et al., 2000), Kaposi's sarcoma virus (KSV) (Wang et al., 2000), human herpesvirus (HHV)-6, -7 (Clark, 2002; Clark et al., 2003; Clark and Griffiths, 2003), cytomegalovirus (CMV) (Michaelides et al., 2002) and EBV (Heslop et al., 1994) are common in immunocompromised individuals.Keywords
This publication has 82 references indexed in Scilit:
- Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cellsJournal of Immunotherapy, 2007
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006
- In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytesBlood, 2006
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's DiseaseJournal of Experimental Medicine, 2004
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphomaInternational Journal of Cancer, 2001
- Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cellsTransplantation and Cellular Therapy, 2001
- MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSINGAnnual Review of Immunology, 1998
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- MHC Class I–Restricted CTL Responses to Exogenous AntigensImmunity, 1996